Oral administration of Porphyromonas gingivalis to mice with diet-induced obesity impairs cognitive function associated with microglial activation in the brain

J Oral Microbiol. 2024 Nov 14;16(1):2419155. doi: 10.1080/20002297.2024.2419155. eCollection 2024.

Abstract

Objective: Both periodontal disease and obesity are risk factors for dementia, but their links to 1brain function remain unclear. In this study, we examined the effects of oral infection with a periodontal pathogen on cognitive function in a mouse model of obesity, focusing on the roles of microglia.

Methods: To create a mouse model of diet-induced obesity and periodontitis, male C57BL/6 J mice were first fed a high-fat diet containing 60% lipid calories for 18 weeks, beginning at 12 weeks of age, to achieve diet-induced obesity. Then, Porphyromonas gingivalis administration in the oral cavity twice weekly for 6 weeks was performed to induce periodontitis in obese mice.

Results: Obese mice orally exposed to P. gingivalis showed cognitive impairment in the novel object recognition test. Increased expression levels of inflammatory cytokines (e.g. interleukin-1β and tumor necrosis factor-α) were observed in the hippocampus of P. gingivalis-treated obese mice. Immunohistochemical analysis revealed that microglia cell body size was increased in the hippocampus and prefrontal cortex of P. gingivalis-treated obese mice, indicating microglial activation. Furthermore, depletion of microglia by PLX3397, a colony-stimulating factor 1 receptor inhibitor, ameliorated cognitive dysfunction.

Conclusion: These results suggest that microglia mediate periodontal infection-induced cognitive dysfunction in obesity.

Keywords: Periodontal disease; Porphyromonas gingivalis; cognitive dysfunction; inflammation; microglia; obesity; oral infection.

Grants and funding

This study was supported in part by JSPS KAKENHI, Grant Numbers [JP20K18669, JP23K091830A (K. Oue), JP 22K09983 (K. Ouhara), JP24K02185 (E.I.), JP20H03392 (Y. A.), JP21K19714 (Y. A.), and JP24K02185 (Y.A.)]; and Grants from the Satake Fund (E. I.), The Nakatomi Foundation (Y. A.), Astellas Foundation for Research on Metabolic Disorders (Y. A.), Takeda Science Foundation (Y. A.), Mochida Memorial Foundation for Medical and Pharmaceutical Research (Y. A.), and Chugai Foundation for Innovative Drug Discovery Science (Y. A.).